Pharmaceutical compositions for sustained drug delivery

Details Pharmaceutical compositions for sustained drug delivery Pharmaceutical compositions for sustained drug delivery

2005-06-30

2011-12-27

Tate, Christopher R. (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S010300, C514S010700, C514S010800

Reexamination Certificate

active

08084419

ABSTRACT:
Sustained delivery formulations comprising a water-insoluble complex of a peptide and a plurality of ligands are disclosed. The formulations of the invention allow for loading of high concentrations of peptide in a small volume and for delivery of a pharmaceutically active peptide for prolonged periods, e.g., one month, after administration of the complex. The complexes of the invention can be milled or crushed to a fine powder. In powdered form, the complexes form stable aqueous suspensions and dispersions, suitable for injection. Methods of making the complexes of the invention, and methods of these complexes are also disclosed.

REFERENCES:
patent: 4489065 (1984-12-01), Walton et al.
patent: 4980150 (1990-12-01), Keith
patent: 5744166 (1998-04-01), Illum
patent: 5747641 (1998-05-01), Frankel et al.
patent: 5763422 (1998-06-01), Lichtenberger et al.
patent: 5804604 (1998-09-01), Frankel et al.
patent: 5830883 (1998-11-01), Block et al.
patent: 5834598 (1998-11-01), Lowman et al.
patent: 5846743 (1998-12-01), Janmey et al.
patent: 5888762 (1999-03-01), Joliot et al.
patent: 5900408 (1999-05-01), Block et al.
patent: 5968895 (1999-10-01), Gefter et al.
patent: 5972326 (1999-10-01), Galin et al.
patent: 6015787 (2000-01-01), Potter et al.
patent: 6054555 (2000-04-01), Engel et al.
patent: 6180608 (2001-01-01), Gefter et al.
patent: 6328979 (2001-12-01), Yamashita et al.
patent: 6699833 (2004-03-01), Gefter et al.
patent: 7037889 (2006-05-01), Gefter
patent: 2002/0086829 (2002-07-01), Gefter
patent: 1053581 (1979-05-01), None
patent: WO-96/39160 (1996-12-01), None
patent: WO-98/25642 (1998-06-01), None
patent: WO-99/10376 (1999-03-01), None
patent: WO-99/29721 (1999-06-01), None
patent: WO-99/55899 (1999-11-01), None
Mezö, G., et al, “Carrier Design: Conformational Studies of Amino Acid (X) and Oligopeptide (X-DL-Alam) Substituted Poly (L-Lysine),”Biopolymers, vol. 33(6):873-885 (1993).
Mezö, G., et al., “Synthesis, Conformationa, Biodistribution, and Hormone-Related in Vitro Antitumor Activity of a Gonadotropin-Releasing Hormone Against-Branched Polypeptide Conjugate,”Bioconjugate Chemistry, vol. 7(6):642-650 (1996).
Ryser, H.J.-P., et al., “Conjugation of Methotrexate to Poly (L-Lysine) as a Potential Way to Overcome Drug Resistance,”Cancer, vol. 45 (5 Suppl.):1207-1211 (1980).
Citro, G., et al., “Chemical Modification of Ligands for Cell Receptors to Introduce Foreign Compounds into the Cells,”Dis. Colon Rectum, vol. 37(Suppl.):S127-S132 (1994).
Lali, A., et al., “Carboxymethyl cellulose as a new heterobifunctional ligand carrier for affinity precipitation of proteins,”Bioseparation, vol. 7:195-205 (1999).

Affiliated with

Also associated with

Rating

Pharmaceutical compositions for sustained drug delivery does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical compositions for sustained drug delivery, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions for sustained drug delivery will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4306369